Company Overview

DiaMedica Inc. is a publicly traded (TSX-V:DMA) clinical stage biopharmaceutical company focused on the discovery and development of novel therapies to treat diabetes and the complications associated with diabetes.

Latest News

DiaMedica to Present at the 2014 GTC Diabetes Summit

15-Apr-2014 – Minneapolis, MN

DiaMedica Inc. (TSX-V:DMA), a clinical stage biopharmaceutical company focused on the treatment of diabetes and its complications, today announced it will be presenting an overview of preclinical and Phase 1 clinical results for its lead product DM199, at the 2014 GTC Diabetes Summit taking place from April 23-25, 2014, in Cambridge, Massachusetts, USA. DiaMedica’s Vice President, Clinical and Regulatory Affairs, Dr. Mark Robbins, will be presenting the data during the Diabetes Drug Discovery & Development session and chairing the session on Clinical Drug Development in Diabetes.

DiaMedica Appoints John Savage as Chief Financial Officer

07-Apr-2014 – Minneapolis, MN

DiaMedica (TSX-V: DMA) today announced the appointment of Mr. John Savage as the Company’s Chief Financial Officer. Mr. Savage has more than 17 years of experience working with publicly traded companies.

DiaMedica Files 20-F Registration Statement with U.S. SEC and Provides Clinical Update

19-Feb-2014 – Minneapolis, MN

DiaMedica (TSX-V:DMA) announced that it has filed a Registration Statement on Form 20-F to register its common shares with the United States Securities and Exchange Commission (the “SEC”). The filing is subject to review by the SEC.

Stock Quote


Subscribe to Email Updates

Get the latest updates from DiaMedica Inc.  Please enter your contact information below to sign up:
Captcha Image